Avacta Group (STU:RTQ1) Moat Score: 4/10 (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:RTQ1 Avacta Group PLC STU:RTQ1
27 GF Score
Price €0.80
! 8 Warning Signs
View Full Analysis

What is Avacta Group Moat Score?

Avacta Group STU:RTQ1 +0.63% 27 Moat Score is 4 as of Jul. 28, 2026. GuruFocus rates STU:RTQ1 with a GF Score™ of 27/100. The stock has 8 warning signs investors should review. Among 1,393 Biotechnology companies, Avacta Group ranks better than 88.8% on this metric.

Avacta Group has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Avacta Group has Narrow Moat: Avacta Group PLC has some valuable intellectual property in the biotech sector, providing modest competitive advantages. However, it lacks strong brand strength and significant market share, limiting its overall moat to a discernible but modest level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Avacta Group might have Narrow Moat - Discernible but modest moat.

Avacta Group  (STU:RTQ1) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Avacta Group Moat Score Related Terms

STU:RTQ1 vs VRTX, REGN, RVMD: Moat Score Comparison

For the Biotechnology subindustry, Avacta Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avacta Group Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Avacta Group's Moat Score falls into.


STU:RTQ1
27GF Score
Avacta Group PLC STU:RTQ1
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Avacta Group (STU:RTQ1) has a Moat Score of 4 as of Jul. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Avacta Group ranks #156 out of 1393 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Avacta Group's Moat Score too high?
Avacta Group's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Avacta Group's value of 4 is 100% above this industry median. Based on the distribution chart, Avacta Group ranks #156 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avacta Group has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #156 out of 1393 companies for Moat Score. This places Avacta Group in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Avacta Group's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Avacta Group (STU:RTQ1) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Avacta Group's overall GF Score™ is 27/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Avacta Group (STU:RTQ1), the current Moat Score is 4 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avacta Group Business Description

Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
27GF Score

Get the complete analysis for STU:RTQ1

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price